![THU-192-All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive noncirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china]()
THU-192-All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive noncirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in chinaWei, Lai; Xu, xiaoyuan; Guan, yujuan; Zheng, sujun; Sheng, Ji-Fang; Yang, xingxiang; Ma, yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng; Li, Jun; Tan, Youwen; He, Qing; Xie, Qing; Wang, Maorong; An, Ping; Gong, Guozhong; Liu, Huimin; Ning, Qin; Hua, Rui; Ning, Bo; Xie, Wen; Zhang, Jiming; Huang, Wenxiang; Yang, Yongfeng; Lin, Minghua; Zhao, Yingren; Yu, Yanhong; Jia, Ji-Dong; Yang, Dongliang; Chen, Liang; Ye, Yinong; Nan, Yuemin; Gong, Zuojong; Zhang, Quan; Hu, Peng; Wang, Fu-Sheng; Li, Yongguo; Li, Dongliang; Jia, Zhansheng; Hou, Jinlin; Chen, Chengwei; Wu, Jinzi · Journal of Hepatology · 2019